1. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395(10223):497–506. PMID:
31986264.
Article
2. Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls. Treasure Island, FL, USA: StatPearls Publishing;2021.
3. Yang X, Yu Y, Xu J, Shu H, Xia J, Liu H, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir Med. 2020; 8(5):475–481. PMID:
32105632.
Article
4. Seong H, Hyun HJ, Yun JG, Noh JY, Cheong HJ, Kim WJ, et al. Comparison of the second and third waves of the COVID-19 pandemic in South Korea: importance of early public health intervention. Int J Infect Dis. 2021; 104:742–745. PMID:
33556610.
Article
5. Khan N, Mahmud N, Trivedi C, Reinisch W, Lewis JD. Risk factors for SARS-CoV-2 infection and course of COVID-19 disease in patients with IBD in the Veterans Affair Healthcare System. Gut. 2021; 70(9):1657–1664. PMID:
33753416.
Article
6. Ludvigsson JF, Axelrad J, Halfvarson J, Khalili H, Larsson E, Lochhead P, et al. Inflammatory bowel disease and risk of severe COVID-19: a nationwide population-based cohort study in Sweden. United European Gastroenterol J. 2021; 9(2):177–192.
Article
7. Kim KO, Jang BI. Management of inflammatory bowel disease in the COVID-19 era. Intest Res. Forthcoming. 2021; DOI:
10.5217/ir.2020.00156.
Article
8. Maconi G, Bosetti C, De Monti A, Boyapati RK, Shelton E, Piazza N, et al. Risk of COVID 19 in patients with inflammatory bowel diseases compared to a control population. Dig Liver Dis. 2021; 53(3):263–270. PMID:
33483259.
Article
9. Hong KH, Lee SW, Kim TS, Huh HJ, Lee J, Kim SY, et al. Guidelines for laboratory diagnosis of coronavirus disease 2019 (COVID-19) in Korea. Ann Lab Med. 2020; 40(5):351–360. PMID:
32237288.
Article
10. Bezzio C, Saibeni S, Variola A, Allocca M, Massari A, Gerardi V, et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020; 69(7):1213–1217. PMID:
32354990.
Article
11. Allocca M, Fiorino G, Zallot C, Furfaro F, Gilardi D, Radice S, et al. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan Cohorts. Clin Gastroenterol Hepatol. 2020; 18(9):2134–2135. PMID:
32360811.
Article
12. Gubatan J, Levitte S, Balabanis T, Patel A, Sharma A, Habtezion A. SARS-CoV-2 testing, prevalence, and predictors of COVID-19 in patients with inflammatory bowel disease in Northern California. Gastroenterology. 2020; 159(3):1141–1144.e2. PMID:
32387541.
Article
13. Lukin DJ, Kumar A, Hajifathalian K, Sharaiha RZ, Scherl EJ, Longman RS. Baseline disease activity and steroid therapy stratify risk of covid-19 in patients with inflammatory bowel disease. Gastroenterology. 2020; 159(4):1541–1544.e2. PMID:
32479824.
Article
14. Taxonera C, Sagastagoitia I, Alba C, Mañas N, Olivares D, Rey E. 2019 novel coronavirus disease (COVID-19) in patients with inflammatory bowel diseases. Aliment Pharmacol Ther. 2020; 52(2):276–283. PMID:
32359205.
Article
15. Singh AK, Jena A, Kumar-M P, Sharma V, Sebastian S. Risk and outcomes of coronavirus disease in patients with inflammatory bowel disease: a systematic review and meta-analysis. United European Gastroenterol J. 2021; 9(2):159–176.
Article
16. Sanyaolu A, Okorie C, Marinkovic A, Patidar R, Younis K, Desai P, et al. Comorbidity and its impact on patients with COVID-19. SN Compr Clin Med. 2020; 1–8.
Article
17. Elshazli RM, Kline A, Elgaml A, Aboutaleb MH, Salim MM, Omar M, et al. Gastroenterology manifestations and COVID-19 outcomes: a meta-analysis of 25,252 cohorts among the first and second waves. J Med Virol. 2021; 93(5):2740–2768. PMID:
33527440.
Article
18. Singh AK, Jena A, Kumar-M P, Jha DK, Sharma V. Clinical presentation of COVID-19 in patients with inflammatory bowel disease: a systematic review and meta-analysis. Intest Res. Forthcoming. 2021; DOI:
10.5217/ir.2020.00108.
Article
19. Patrì A, Pinchera B, Spirito L, Delfino M, Imbimbo C, Salvatore P, et al. Gastrointestinal tract diseases as a risk factor for SARSCoV2 rectal shedding? An Italian report on 10 COVID-19 patients. Intest Res. 2021; 19(3):354–356. PMID:
33147898.
Article
20. Barbosa da Luz B, de Oliveira NMT, França Dos Santos IW, Paza LZ, Braga LLVM, Platner FDS, et al. An overview of the gut side of the SARS-CoV-2 infection. Intest Res. 2021; 19(4):379–385. PMID:
33142370.
Article
21. Lukin DJ, Funez-dePagnier G, Lima S, Lai D, Duenas-Bianchi L, Ahmed W, et al. No durable impact of COVID-19 on intestinal disease activity in subjects with IBD. Clin Gastroenterol Hepatol. 2021; 19(11):2312–2314.e3. PMID:
34102340.
Article
22. Brenner EJ, Ungaro RC, Gearry RB, Kaplan GG, Kissous-Hunt M, Lewis JD, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020; 159(2):481–491.e3. PMID:
32425234.
Article
23. Allocca M, Chaparro M, Gonzalez HA, Bosca-Watts MM, Palmela C, D'Amico F, et al. Patients with inflammatory bowel disease are not at increased risk of COVID-19: a large multinational cohort study. J Clin Med. 2020; 9(11):3533.
Article
24. Attauabi M, Seidelin J, Burisch J. Danish COVID-IBD Study Group. Association between 5-aminosalicylates in patients with IBD and risk of severe COVID-19: an artefactual result of research methodology? Gut. 2021; 70(10):2020–2022. PMID:
33658323.
Article
25. Allez M, Fleshner P, Gearry R, Lakatos PL, Rubin DT. Care of the patient with IBD requiring hospitalisation during the COVID-19 pandemic. J Crohns Colitis. 2020; 14(14 Suppl 3):S774–S779. PMID:
32722757.
Article
26. Magro F, Rahier JF, Abreu C, MacMahon E, Hart A, van der Woude CJ, et al. Inflammatory bowel disease management during the COVID-19 outbreak: the ten do's and don'ts from the ECCO-COVID taskforce. J Crohns Colitis. 2020; 14(14 Suppl 3):S798–S806. PMID:
32722754.
Article
27. Gajendran M, Perisetti A, Aziz M, Raghavapuram S, Bansal P, Tharian B, et al. Inflammatory bowel disease amid the COVID-19 pandemic: impact, management strategies, and lessons learned. Ann Gastroenterol. 2020; 33(6):591–602. PMID:
33162736.
Article
28. Chen Y, Yu Q, Farraye FA, Kochhar GS, Bernstein CN, Navaneethan U, et al. Patterns of endoscopy during COVID-19 pandemic: a global survey of interventional inflammatory bowel disease practice. Intest Res. 2021; 19(3):332–340. PMID:
32475088.
Article
29. Fukuda T, Naganuma M, Kanai T. Current new challenges in the management of ulcerative colitis. Intest Res. 2019; 17(1):36–44. PMID:
30678445.
Article
30. Ooi CJ, Hilmi I, Banerjee R, Chuah SW, Ng SC, Wei SC, et al. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia. Intest Res. 2019; 17(3):285–310. PMID:
31146509.
Article